ScreenerHero

MREO Mereo BioPharma Group plc

NAS · US · Healthcare · Biotechnology · mereobiopharma.com
0.3528USD+0.77%Mkt Cap: 56.34M $P/E: —

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap56.34M USD
Enterprise Value26.82M USD
Revenue (TTM)0 USD
Gross Profit367.00K USD
Net Income (TTM)-41.88M USD
Revenue/Share0.00 USD
Last Price0.3528 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees39
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.26
PEG—
EV/EBITDA-0.83
EV/Revenue—
P/SInfinity
P/B1.94
EPS (TTM)-0.20
EPS (Forward)-0.02
52W Range
0.20007% of range2.370
52W High2.370 USD
52W Low0.2000 USD
Profitability
Gross Margin73.40%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-8375.60%
ROE-102.35%
ROA-91.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.97M USD
CapEx (TTM)320.00K USD
FCF Margin—
FCF Yield-24.24%
Net Debt-29.09M USD
Net Debt/EBITDA0.90
Balance Sheet
Debt/Equity0.00
Current Ratio5.88
Quick Ratio5.64
Book Value/Sh0.18 USD
Cash/Share0.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)1.966 USD
Upside (mean)+457.2%
Target Range0.9816 USD – 2.975 USD
0.9816+457.2% to mean2.975
# Analysts5
Ownership
Shares Out.159.69M
Float125.02M
Insiders0.75%
Institutions35.47%
Short Interest
Short Ratio2.3d
Short % Float2.37%
Short % Out.1.93%
Shares Short3.08M
Short (prev mo.)4.32M
Technical
SMA 500.3047 (+15.8%)
SMA 2000.4074 (-13.4%)
Beta0.14
S&P 52W Chg15.78%
Avg Vol (30d)1.67M
Avg Vol (10d)2.09M
Technical Indicators
RSI (14)55.4
MACD0.0217
MACD Signal0.0190
MACD Hist.+0.0027
BB Upper0.4273 USD
BB Middle0.3263 USD
BB Lower0.2253 USD
BB Width61.89%
ATR (14)0.0312 USD
Vol Ratio (20d)0.57x